Getting to IND faster has become an industry expectation—but acceleration without the right strategy can amplify risk. In this on-demand webinar, Lonza experts show how sponsors can take biologic programs from DNA to IND readiness in as little as 6 months, without compromising CMC robustness, regulatory confidence, or long-term scalability.
The webinar focuses on how speed is actually achieved: through high-performing expression systems, earlier decision-making with rapid toxicology data, integrated planning across cell line, drug substance, drug product, and analytics, and parallelized execution that removes months of avoidable delay from traditional development paths.
If speed to IND is critical for your program, this webinar will help you:
- Understand where time is most often lost in early biologics development, and how expertise helps to eliminate those bottlenecks
- Learn how integrated DNA-to-IND strategies can support funding milestones, investor expectations, and competitive positioning
- See how acceleration can be achieved without increasing CMC or regulatory risk, even under aggressive timelines
- Evaluate when a 6-month vs. 8-month DNA-to-IND pathway may be appropriate for your molecule and development goals
- Learn how an integrated CDMO partnership can strengthen program design, streamline tech transfer, and support rapid, predictable progression to IND
- Gain insight into how early choices impact not just IND submission, but post-IND scale-up and viability for commercial manufacturing
